Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Recipient : Honeywell
Deal Size : Undisclosed
Deal Type : Agreement
Honeywell to Power DevPro’s Next-generation Low-Emission Respiratory Inhaler
Details : The agreement will support development of DP007 (albuterol) inhalation aerosol indicated for bronchospasm in patients 4 years of age & older with reversible obstructive airway disease.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 10, 2024
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Recipient : Honeywell
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Solrikitug
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Recipient : Uniquity Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
July 11, 2024
Lead Product(s) : Solrikitug
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Recipient : Uniquity Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NSI-8226
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Recipient : Uniquity Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Solriktug in Adult Participants With Asthma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 11, 2024
Lead Product(s) : NSI-8226
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Recipient : Uniquity Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Early feasibility studies on climate-friendly albuterol inhaler completed
Details : DP007 inhalation aerosol is a beta2-adrenergic agonist indicated for the treatment of bronchospasm in patients 4 years of age & older with reversible obstructive airway disease.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 11, 2024
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AP01
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Recipient : Avalyn Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 25, 2024
Lead Product(s) : AP01
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Recipient : Avalyn Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Axatilimab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Recipient : Syndax Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 15, 2023
Lead Product(s) : Axatilimab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Recipient : Syndax Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amphotericin B Cystetic
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Recipient : Cystetic Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 06, 2023
Lead Product(s) : Amphotericin B Cystetic
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Recipient : Cystetic Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable